Payment overview · 2025
General Payments
$125.00
1 reported records · 1 companies
Healthcare provider profile · identity verified
David Matthew Balot, D.O
Allopathic & Osteopathic Physicians|Family Medicine · LINDENHURST, NY · NPI 1649619636
Verified facts
What the public records show
CMS Open Payments records show David Matthew Balot, D.O received $125.00 in general payments during 2025 across 1 reported records.
ABBVIE INC. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $125.00 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $125.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Furosemide | Furosemide | 871 | 140 |
| Levothyroxine Sodium | Levothyroxine Sodium | 794 | 107 |
| Amlodipine Besylate | Amlodipine Besylate | 639 | 143 |
| Atorvastatin Calcium | Atorvastatin Calcium | 539 | 172 |
| Metoprolol Succinate | Metoprolol Succinate | 480 | 109 |
| Famotidine | Famotidine | 456 | 82 |
| Losartan Potassium | Losartan Potassium | 439 | 88 |
| Gabapentin | Gabapentin | 437 | 81 |
| Pantoprazole Sodium | Pantoprazole Sodium | 433 | 130 |
| Eliquis | Apixaban | 421 | 92 |
| Mirtazapine | Mirtazapine | 378 | 55 |
| Escitalopram Oxalate | Escitalopram Oxalate | 362 | 56 |
| Potassium Chloride | Potassium Chloride | 362 | 86 |
| Metoprolol Tartrate | Metoprolol Tartrate | 335 | 71 |
| Sertraline Hcl | Sertraline Hcl | 320 | 48 |
| Metformin Hcl | Metformin Hcl | 294 | 73 |
| Warfarin Sodium | Warfarin Sodium | 264 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 229 | 35 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 179 | 67 |
| Oxycodone Hcl | Oxycodone Hcl | 174 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 173 | 27 |
| Xarelto | Rivaroxaban | 168 | 18 |
| Prednisone | Prednisone | 148 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 147 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 145 | 45 |
| Simvastatin | Simvastatin | 142 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 138 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 136 | 59 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 135 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 128 | 38 |
| Buspirone Hcl | Buspirone Hcl | 120 | 11 |
| Omeprazole | Omeprazole | 119 | 50 |
| Memantine Hcl | Memantine Hcl | 116 | 20 |
| Levetiracetam | Levetiracetam | 107 | 22 |
| Finasteride | Finasteride | 101 | 23 |
| Januvia | Sitagliptin Phosphate | 101 | 18 |
| Olanzapine | Olanzapine | 97 | suppressed |
| Alprazolam | Alprazolam | 96 | 33 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 93 | 15 |
| Lisinopril | Lisinopril | 93 | 30 |
| Latanoprost | Latanoprost | 91 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 90 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 87 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 81 | 14 |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 79 | 65 |
| Santyl | Collagenase Clostridium Hist. | 79 | 20 |
| Carvedilol | Carvedilol | 78 | 24 |
| Allopurinol | Allopurinol | 77 | 28 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 77 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 77 | 21 |
| Glimepiride | Glimepiride | 74 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 70 | 17 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 69 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 69 | 31 |
| Sodium Chloride | 0.9 % Sodium Chloride | 69 | 31 |
| Spironolactone | Spironolactone | 68 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 67 | suppressed |
| Torsemide | Torsemide | 63 | 24 |
| Alendronate Sodium | Alendronate Sodium | 60 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 58 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 58 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 57 | 18 |
| Bupropion Xl | Bupropion Hcl | 56 | suppressed |
| Entresto | Sacubitril/Valsartan | 56 | 12 |
| Azithromycin | Azithromycin | 55 | 36 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 55 | 15 |
| Mupirocin | Mupirocin | 54 | 19 |
| Silver Sulfadiazine | Silver Sulfadiazine | 54 | 15 |
| Baclofen | Baclofen | 53 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 53 | 17 |
| Atenolol | Atenolol | 52 | 14 |
| Nystatin | Nystatin | 52 | 26 |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 52 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 51 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 51 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 50 | suppressed |
| Lamotrigine | Lamotrigine | 50 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 50 | 18 |
| Propranolol Hcl | Propranolol Hcl | 50 | suppressed |
| Sucralfate | Sucralfate | 49 | 16 |
| Trazodone Hcl | Trazodone Hcl | 49 | 18 |
| Jardiance | Empagliflozin | 47 | 11 |
| Lactulose | Lactulose | 46 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 45 | suppressed |
| Telmisartan | Telmisartan | 45 | suppressed |
| Digoxin | Digoxin | 43 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 42 | 21 |
| Enalapril Maleate | Enalapril Maleate | 42 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 42 | 16 |
| Meloxicam | Meloxicam | 40 | 11 |
| Rexulti | Brexpiprazole | 40 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 39 | suppressed |
| Budesonide | Budesonide | 39 | suppressed |
| Methotrexate | Methotrexate Sodium | 39 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 39 | 39 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 38 | suppressed |
| Ezetimibe | Ezetimibe | 37 | suppressed |
| Metolazone | Metolazone | 37 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 37 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 36 | 26 |
| Cephalexin | Cephalexin | 36 | 30 |
| Divalproex Sodium | Divalproex Sodium | 35 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 34 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Valsartan | Valsartan | 34 | 11 |
| Dorzolamide Hcl | Dorzolamide Hcl | 33 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 22 |
| Nystop | Nystatin | 32 | 13 |
| Anastrozole | Anastrozole | 31 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 31 | 16 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 31 | suppressed |
| Ramipril | Ramipril | 31 | suppressed |
| Ssd | Silver Sulfadiazine | 31 | 16 |
| Clonazepam | Clonazepam | 30 | suppressed |
| Risperidone | Risperidone | 30 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 29 | suppressed |
| Propylthiouracil | Propylthiouracil | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Cilostazol | Cilostazol | 27 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 27 | 11 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 27 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 26 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Hydrocortisone | Hydrocortisone | 26 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Bicalutamide | Bicalutamide | 24 | suppressed |
| Darifenacin Er | Darifenacin Hydrobromide | 24 | suppressed |
| Dextrose In Water | Dextrose 5 % In Water | 24 | 13 |
| Insulin Lispro | Insulin Lispro | 23 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 14 |
| Procrit | Epoetin Alfa | 23 | suppressed |
| Ertapenem | Ertapenem Sodium | 22 | 12 |
| Incruse Ellipta | Umeclidinium Bromide | 22 | suppressed |
| Timolol Maleate | Timolol Maleate | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | suppressed |
| Atovaquone | Atovaquone | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Haloperidol | Haloperidol | 19 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 13 |
| Ofloxacin | Ofloxacin | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Aranesp | Darbepoetin Alfa In Polysorbat | 17 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 17 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | 11 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 16 | suppressed |
| Levemir | Insulin Detemir | 16 | suppressed |
| Mesalamine | Mesalamine | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Lumigan | Bimatoprost | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 14 | 11 |
| Ethambutol Hcl | Ethambutol Hcl | 14 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 14 | suppressed |
| Leflunomide | Leflunomide | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 14 | suppressed |
| Scopolamine | Scopolamine | 14 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Tadalafil | Tadalafil | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 12 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 11 | suppressed |
| Insulin Aspart | Insulin Aspart | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Neupro | Rotigotine | 11 | suppressed |
| Solu-Medrol | Methylprednisolone Sod Succ/Pf | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $125.00 · 1 records | ABBVIE INC. | AVYCAZ | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error